조직 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Tissue Diagnostics Market size is expected to reach USD 15.78 Billion in 2034 from USD 7.24 Billion (2025) growing at a CAGR of 9.04% during 2026-2034.

The tissue diagnostics market is poised for significant growth, driven by the increasing prevalence of cancer and the rising demand for accurate and timely diagnostic solutions. As healthcare providers seek to improve patient outcomes through early detection and personalized treatment plans, the need for advanced tissue diagnostic technologies is surging. Innovations in histopathology, immunohistochemistry, and molecular diagnostics are enhancing the accuracy and efficiency of tissue analysis, enabling healthcare professionals to make informed decisions regarding patient care. The integration of digital pathology and artificial intelligence is further transforming the landscape, allowing for more precise image analysis and improved workflow in laboratories.

Moreover, the growing emphasis on personalized medicine is influencing the tissue diagnostics market. As the understanding of cancer biology advances, there is a rising demand for diagnostic tests that can identify specific biomarkers associated with different cancer types. This trend is driving the development of companion diagnostics that guide treatment decisions and improve therapeutic outcomes. Additionally, the increasing focus on research and development in oncology is fostering innovation in tissue diagnostics, leading to the introduction of novel assays and technologies that enhance diagnostic capabilities.

Furthermore, the rise of awareness campaigns and initiatives aimed at improving cancer screening and diagnosis is contributing to the growth of the tissue diagnostics market. As patients become more informed about the importance of early detection, the demand for reliable and accessible diagnostic solutions is expected to rise. Collaborations between academic institutions, research organizations, and industry players are also driving advancements in tissue diagnostics, ensuring that new technologies meet the evolving needs of healthcare providers and patients.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Consumables (Antibodies, Kits, Reagents, Probes)
• InstrumentsA (Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments (Automated Cover Slippers, Microtomes, Embedding Systems, Paraffin Dispensers, And Slide Labelers))

By Technology

• Immunohistochemistry
• In Situ Hybridization
• Digital Pathology & Workflow Management
• Special Staining

By Disease Type

• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-small Cell Lung Cancer
• Other Disease Types (Neurological Disease, Cardiovascular Disease, Immunological Diseases, Infectious Diseases, Cancers Of The Bone, Colon, Thyroid, Cervix, And Skin, Gallbladder Carcinoma, Hbv, Epstein-Barr Virus, Hepatitis, Muscular Dystrophy, Renal Cell Carcinoma, And Pleomorphic Sarcomas.)

By End User

• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Other End Users (Reference Laboratories And Academic Research Laboratories)

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Danaher Corporation, PHC Holdings Corporation, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, GE Healthcare, Cell Signaling Technology, Inc, BioGenex, Siemens

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TISSUE DIAGNOSTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Consumables (Antibodies, Kits, Reagents, Probes) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. InstrumentsA (Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments (Automated Cover Slippers, Microtomes, Embedding Systems, Paraffin Dispensers, And Slide Labelers)) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TISSUE DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Immunohistochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In Situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Digital Pathology & Workflow Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Special Staining Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TISSUE DIAGNOSTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Type
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gastric Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Non-small Cell Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Disease Types (Neurological Disease, Cardiovascular Disease, Immunological Diseases, Infectious Diseases, Cancers Of The Bone, Colon, Thyroid, Cervix, And Skin, Gallbladder Carcinoma, Hbv, Epstein-Barr Virus, Hepatitis, Muscular Dystrophy, Renal Cell Carcinoma, And Pleomorphic Sarcomas.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TISSUE DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Contract Research Organizations (CROs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other End Users (Reference Laboratories And Academic Research Laboratories) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL TISSUE DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Technology
  • 8.2.3 By Disease Type
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Technology
  • 8.3.3 By Disease Type
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Technology
  • 8.4.3 By Disease Type
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Technology
  • 8.5.3 By Disease Type
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Technology
  • 8.6.3 By Disease Type
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TISSUE DIAGNOSTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche Ltd
  • 10.2.2 Danaher Corporation
  • 10.2.3 PHC Holdings Corporation
  • 10.2.4 Agilent Technologies Inc
  • 10.2.5 Thermo Fisher Scientific Inc
  • 10.2.6 Abbott Laboratories
  • 10.2.7 GE Healthcare
  • 10.2.8 Cell Signaling TechnologyInc
  • 10.2.9 BioGenex
  • 10.2.10 Siemens